POT-4

CAT:
804-HY-P3204-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
POT-4 - image 1

POT-4

  • Description :

    POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research[1][2]
  • CAS Number :

    [934461-40-2]
  • Product Name Alternative :

    AL-78898A
  • UNSPSC :

    12352209
  • Target :

    Complement System
  • Type :

    Peptides
  • Related Pathways :

    Immunology/Inflammation
  • Applications :

    Metabolism-protein/nucleotide metabolism
  • Field of Research :

    Metabolic Disease
  • Assay Protocol :

    https://www.medchemexpress.com/pot-4.html
  • Purity :

    98.88
  • Solubility :

    DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)
  • Smiles :

    C(C=1C=2C(N(C)C1)=CC=CC2)[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=4C=5C(NC4)=CC=CC5)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CN=CN6)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)CSSC[C@H](NC([C@H]([C@H](CC)C)NC(C)=O)=O)C(=O)N[C@@H](C(C)C)C(=O)N3
  • Molecular Formula :

    C72H102N22O18S2
  • Molecular Weight :

    1627.85
  • References & Citations :

    [1]S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.|[2]Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40 (1) :18-26.
  • Shipping Conditions :

    Blue Ice
  • Storage Conditions :

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Scientific Category :

    Peptides
  • Clinical Information :

    Phase 2

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide